Behind the Paper
The real stories behind the latest research papers, from conception to publication, the highs and the lows
Mutation in Bruton Tyrosine Kinase (BTK) A428D Confers Resistance To BTK-Degrader Therapy In Chronic Lymphocytic Leukemia
Drugs that target BTK for proteasomal degradation, so-call BTK degraders, are presumed able to mitigate the risk of drug resistance due to BTK mutations. In Leukemia 38:1818 (2024), Kipps and colleagues describe a patient who developed resistance to the BTK-degrader BGB-16673 via a mutation in BTK.
How machine learning helped us uncover key environmental and clinical risk factors to child health
The environment in which a child grows up affects its development and well-being later in life. These effects do not happen in isolation – whether due to air pollution, exposure to cleaning products, or a family's social capital, they all simultaneously impact a child's health.
